- NetScientific, the biomedical and healthcare technology investment group, is pleased to announce that, to complement and reinforce its personalised medicine platform, Nanopore-II (a new US division of NetScientific) has secured an important research programme in DNA sequencing with a research institute in the United States.

This programme is in a fast-growing, valuable and very competitive field. Notwithstanding the crowded IP landscape, feedback from the US Patent Office on the initial filings is encouraging.

Story provided by